Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. announced that they have temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR). This decision was taken in alignment with the U.S...
More...
Linear Mode
